Literature DB >> 20514492

BRAF mutation predicts resistance to anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer.

Chen Mao, Ru-Yan Liao, Qing Chen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20514492     DOI： 10.1007/s00432-010-0922-8

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN： 0171-5216            Impact factor:   4.553


× No keyword cloud information.
  4 in total

1.  Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

Authors:  Pierre Laurent-Puig; Anne Cayre; Gilles Manceau; Emmanuel Buc; Jean-Baptiste Bachet; Thierry Lecomte; Philippe Rougier; Astrid Lievre; Bruno Landi; Valérie Boige; Michel Ducreux; Marc Ychou; Fréderic Bibeau; Olivier Bouché; Julia Reid; Steven Stone; Frédérique Penault-Llorca
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544

2.  Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

Authors:  Federica Di Nicolantonio; Miriam Martini; Francesca Molinari; Andrea Sartore-Bianchi; Sabrina Arena; Piercarlo Saletti; Sara De Dosso; Luca Mazzucchelli; Milo Frattini; Salvatore Siena; Alberto Bardelli
Journal:  J Clin Oncol       Date:  2008-11-10       Impact factor: 44.544

3.  Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer.

Authors:  Andrea Sartore-Bianchi; Federica Di Nicolantonio; Michele Nichelatti; Francesca Molinari; Sara De Dosso; Piercarlo Saletti; Miriam Martini; Tiziana Cipani; Giovanna Marrapese; Luca Mazzucchelli; Simona Lamba; Silvio Veronese; Milo Frattini; Alberto Bardelli; Salvatore Siena
Journal:  PLoS One       Date:  2009-10-02       Impact factor: 3.240

4.  KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.

Authors:  F Loupakis; A Ruzzo; C Cremolini; B Vincenzi; L Salvatore; D Santini; G Masi; I Stasi; E Canestrari; E Rulli; I Floriani; K Bencardino; N Galluccio; V Catalano; G Tonini; M Magnani; G Fontanini; F Basolo; A Falcone; F Graziano
Journal:  Br J Cancer       Date:  2009-07-14       Impact factor: 7.640
  4 in total
  3 in total

1.  BRAF p.Val600Glu (V600E) Testing for Assessment of Treatment Options in Metastatic Colorectal Cancer.

Authors:  Andrew Lea; Diane Allingham-Hawkins; Susan Levine
Journal:  PLoS Curr       Date:  2010-10-19

2.  Mutations of the functional ARH1 allele in tumors from ARH1 heterozygous mice and cells affect ARH1 catalytic activity, cell proliferation and tumorigenesis.

Authors:  J Kato; D Vekhter; J Heath; J Zhu; J T Barbieri; J Moss
Journal:  Oncogenesis       Date:  2015-06-01       Impact factor: 7.485

3.  BRAF-Mutated Colorectal Cancer Exhibits Distinct Clinicopathological Features from Wild-Type BRAF-Expressing Cancer Independent of the Microsatellite Instability Status.

Authors:  Min Hye Jang; Sehun Kim; Dae Yong Hwang; Wook Youn Kim; So Dug Lim; Wan Seop Kim; Tea Sook Hwang; Hye Seung Han
Journal:  J Korean Med Sci       Date:  2017-01       Impact factor: 2.153
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.